Summary of the Key Points
This article focuses on the concept of “customized babies,” emphasizing that gene editing technology, particularly CRISPR-Cas9, has made it possible to design babies. However, this raises ethical issues such as social stratification (where the wealthy monopolize genetic advantages) and unknown risks. Compared to AI, gene editing is easier to regulate, but it should be integrated into the public health system rather than the private market to ensure fairness and safety.
1. Gene Editing Technology: From Treating Diseases to the Possibility of “Customized Babies”
Gene editing is not a new concept, but CRISPR-Cas9 has made it more precise and straightforward. It’s like giving genes “GPS” and “scissors”—first, guide RNA is used to locate specific segments in the genome, and then the Cas9 enzyme cuts or replaces those segments. The applications are vast: it can disable disease-causing genes (e.g., treating sickle cell anemia), improve crops, develop customized vaccines, and even modify genes at the embryonic stage, which is where the idea of “customized babies” originates. There are two types of embryo editing: one that only affects the child (somatic editing) and another that can be passed on to future generations (germline editing), with the latter being more concerning.
2. The Concerns of Customized Babies: A Genetic Gap Between the Rich and the Poor
The real fear is not the technology itself, but the fact that only the wealthy can afford it. Companies already offer embryo screening services, allowing parents of IVF babies to choose embryos with better genes (e.g., smarter or healthier). If this becomes widespread, the wealthy will accumulate genetic advantages over generations: their children will be smarter, more successful, and earn more money, which they can use to further edit their offspring’s genes, creating a “genetically privileged class.” Moreover, AI could lead to mass unemployment among the poor, making it even harder for them to compete with the genetically enhanced wealthy. This would create a society with a clear genetic divide, potentially more difficult to bridge than the current wealth gap.
3. Prohibition Is Not the Solution: We Are Already “Designing” Life
Some suggest banning germline editing, but the author argues against this. After all, we have been intervening in nature for a long time—vaccines prevent diseases (altering the body’s resistance), and pregnant women undergo Down syndrome screenings to choose healthier fetuses. The lines between these practices and gene editing are blurred. For example, making children genetically resistant to smallpox through gene editing is essentially no different from using vaccines. The real issues are: 1) the unknown risks of gene editing (e.g., altered resistance to smallpox might make them more susceptible to other diseases); 2) the unfairness of only the wealthy being able to afford it.
4. How to Avoid Disaster? Public Health-Oriented Regulation Is Key
The author proposes two solutions:
- Thorough Risk Assessment: Gene editing is much more complex than vaccines, so a stricter approval process is needed, similar to that for pharmaceuticals (e.g., the FDA), to ensure there are no unknown side effects, especially those that could be passed on to future generations.
- Legislation to Restrict Private Services and Promote Public Access: Ban private companies from offering “customized baby” services and make safe and effective gene editing available as a public health initiative. Everyone should have access to it for free or at a low cost, regardless of income, so the wealthy do not monopolize genetic advantages.
5. Comparing Gene Editing and AI: Why Gene Editing Is Easier to Regulate?
Regulating gene editing is less challenging than regulating AI for several reasons:
- There are established regulatory bodies for gene editing (e.g., the National Academy of Sciences in the U.S., the FDA, and international conferences that have issued guidelines), and scientists place more emphasis on ethical issues.
- AI does not yet have a unified regulatory framework, and many companies and researchers are unclear about its social implications.
However, both technologies are related (AI can help in selecting gene combinations), so reaching a consensus on AI ethics is also crucial. Otherwise, we might sacrifice the fair future of future generations for short-term benefits.
The core message of this article is that technology itself is not inherently harmful; it’s the potential for a few to monopolize its benefits that can lead to disaster. Making gene editing a public welfare initiative is the best way to both harness its potential and avoid risks.